Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study
Open Access
- 15 December 2004
- Vol. 330 (7482) , 65
- https://doi.org/10.1136/bmj.38285.482350.82
Abstract
Objective To assess the association between different types of organisation and the results from economic evaluations. Design Retrospective pairwise comparison of evidence submitted to the technology appraisal programme of the National Institute for Clinical Excellence (NICE) by manufacturers of the relevant healthcare technologies and by contracted university based assessment groups. Data sources Data from the first 62 appraisals. Main outcome measure Incremental cost effectiveness ratios. Results Data from 27 of the 62 appraisals could be compared. The analysis of 54 pairwise comparisons showed that manufacturers' estimates of incremental cost effectiveness ratios were lower (suggesting a more cost effective use of resources) than those produced by the assessment groups (25 were lower, 29 were the same, none were higher, P < 0.01). Restriction of this dataset to include only one pairwise comparison per appraisal (27 pairs) produced a similar result (21 were lower, two were the same, four were higher, P < 0.001). Conclusions The estimated incremental cost effectiveness ratios submitted by manufacturers were on average significantly lower than those submitted by the assessment groups. These results show that an important role of NICE's appraisal committee, and of decision makers in general, is to determine which economic evaluations, or parts of evaluations, should be given more credence.Keywords
This publication has 10 references indexed in Scilit:
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Association of Funding and Conclusions in Randomized Drug TrialsJAMA, 2003
- Pharmaceutical industry sponsorship and research outcome and quality: systematic reviewBMJ, 2003
- The ISPOR Good Practice Modeling Principles—A Sensible Approach: Be Transparent, Be ReasonableValue in Health, 2003
- Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux DiseaseMedical Decision Making, 2002
- NICE: faster access to modern treatments? Analysis of guidance on health technologiesBMJ, 2001
- Handling Uncertainty in Cost-Effectiveness ModelsPharmacoEconomics, 2000
- Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in OncologyJAMA, 1999
- The effectiveness of cost-effectiveness analysis in containing costsJournal of General Internal Medicine, 1998
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994